Trials / Conditions / Solid Malignancies

Solid Malignancies

21 registered clinical trials studyying Solid Malignancies — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer NCT07505771	Immunome, Inc.	EARLY_Phase 1
Recruiting	Safety and Tolerability of CMAB017 In Patients With Advanced Solid Tumors NCT06933069	Taizhou Mabtech Pharmaceutical Co.,Ltd	Phase 1
Recruiting	A Phase 1 Study of IM-1021 in Participants With Advanced Cancer NCT06823167	Immunome, Inc.	Phase 1
Recruiting	A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors NCT06725381	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Phase 1
Recruiting	A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies NCT06600789	Carrick Therapeutics Limited	Phase 1 / Phase 2
Recruiting	PET Image Exploration of Novel Tracer [68Ga]-FAPI-JNU Imaging Studies in Patients with Malignant Tumors NCT06684028	Affiliated Hospital of Jiangnan University	N/A
Completed	To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malig NCT05866354	Zai Lab (Shanghai) Co., Ltd.	Phase 1
Active Not Recruiting	Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination NCT05006794	Gilead Sciences	Phase 1
Unknown	The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies NCT04492735	Roshni Dasgupta	—
Completed	Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Do NCT02640755	AstraZeneca	Phase 1
Active Not Recruiting	Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standar NCT02537418	Canadian Cancer Trials Group	Phase 1
Completed	FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression NCT02325739	Novartis Pharmaceuticals	Phase 1 / Phase 2
Completed	Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dos NCT01540526	University of Wisconsin, Madison	Phase 1
Completed	A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an E NCT01202370	University of Kentucky	Phase 1
Terminated	Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours NCT01112397	AstraZeneca	Phase 1
Completed	A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced NCT00676299	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 1
Terminated	Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children NCT00695370	University Hospital, Clermont-Ferrand	Phase 2
Completed	Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies. NCT00162136	R-Pharm	Phase 1
Unknown	Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma NCT00090727	Novacea	Phase 1
Completed	This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Solid Tumor NCT00033202	Sigma-Tau Research, Inc.	Phase 1
Unknown	Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5) NCT00751894	University Hospital, Clermont-Ferrand	Phase 2